Comparison of the effects of two drugs, clonidine and dexmethodomidine, in the treatment of opiate withdrawal syndrome

Comparison of the effects of two drugs, clonidine and dexmethodomidine, in the treatment of opiate withdrawal syndrome in patients admitted to the Toxicology ICU of Luqman Hakim Hospital from 2023 to 2025

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220305054196N3

Enrollment

Registered

2023-05-18

Start date

2023-05-21

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opium withdrawal syndrome. Opioid dependence with withdrawal

Interventions

Intervention 1: Intervention group: In the first group, dexmethodomidine drug at the rate of 0.5 micrograms/kg manufactured by Elixir Pharmaceutical Company will be used. Intervention 2: Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with opium addiction Hospitalization in the poisoning ICU With age minimum 18 and maximum 75 years who have suffered withdrawal syndrome during hospitalization

Exclusion criteria

Exclusion criteria: Lack of consent of the patient to participate in the evaluation Contraindications to clonidine or dexmethodomidine

Design outcomes

Primary

Measure	Time frame
Symptoms of Opium withdrawal syndrome. Timepoint: Before drug administration and 12 and 24 hours later. Method of measurement: Based on COWS checklist criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzade Memarian

Shahid Beheshti University of Medical Sciences

A.memarian@gmail.com+98 21 5541 8175

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026